PI Warkentin
About
In The Last Decade
PI Warkentin
27 papers receiving 677 citations
Peers
Comparison fields: 5 of 55
- Hematology 589
- Oncology 201
- Public Health, Environmental and Occupational Health 175
- Genetics 139
- Immunology 137
Countries citing papers authored by PI Warkentin
This map shows the geographic impact of PI Warkentin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PI Warkentin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PI Warkentin more than expected).
Fields of papers citing papers by PI Warkentin
This network shows the impact of papers produced by PI Warkentin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PI Warkentin. The network helps show where PI Warkentin may publish in the future.
Co-authorship network of co-authors of PI Warkentin
This figure shows the co-authorship network connecting the top 25 collaborators of PI Warkentin. A scholar is included among the top collaborators of PI Warkentin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PI Warkentin. PI Warkentin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 28 | |
| 3 | 35 | |
| 4 | 24 | |
| 5 | 20 | |
| 6 | 17 | |
| 7 | 5 | |
| 8 | American Society for Blood and Marrow Transplantation guidelines for clinical centers. | 3 |
| 9 | Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia. | 6 |
| 10 | 19 | |
| 11 | Allogeneic transplantation of blood-derived, T cell-depleted hemopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. | 112 |
| 12 | 69 | |
| 13 | In vitro treatment of autologous bone marrow for neuroblastoma patients with anti GD2 monoclonal antibody and human complement: a pilot study. | 6 |
| 14 | Bone marrow transplantation for acute leukemia and lymphoma with high-dose cytosine arabinoside and total body irradiation. | 21 |
| 15 | Oropharyngeal Candida prophylaxis in pediatric bone marrow transplant patients. | 14 |
| 16 | Role of the blood bank in bone marrow transplantation. | 3 |
| 17 | 5 | |
| 18 | 82 | |
| 19 | High dose methotrexate (MTX) hepatotoxicity: Significance of frequency of administration | 6 |
| 20 | Acute hepatocellular injury after high dose methotrexate (MTX) infusions | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.